Slide 1: Corporate presentation
Corporate presentation March 2017 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Research - Ultrasonic Blood Flow Monitoring1
Slide 2: Who is Compumedics?
Who is Compumedics? A leading global, innovative developer and manufacturer of medical devices for: Monitoring neurological Ultrasonic monitoring Diagnosing disorders including Highly sophisticated of blood flow through sleep disorders long-term epilepsy brain research the brain (Transcranial monito
Slide 3: H1 FY2017 – Performance Review
H1 FY2017 – Performance Review H1 FY17 Revenue (reported) $16.2m, EBITDA (reported) $1.2m, NPAT (reported) $0.2m H1 FY17 H1 FY16 Variance Comment US sales (11) % on PCP and new leadership Revenue - now in place. DWL Europe also experienced $16.2m $17.4m (7)%* reported some delayed sales which have
Slide 4: H1 FY2017 – Performance Review
H1 FY2017 – Performance Review New leadership in place in US. US sales H1 FY2017 11% below pcp. US business remains on track, with strong pipeline. New Grael platform released and now shipping. Expect improved H2 Germany based DWL experienced sales delays. Has since recouped some of that delayed
Slide 5: Sales Bridge Chart – H1 FY16 versus H1 FY17
Sales Bridge Chart – H1 FY16 versus H1 FY17 20 18 16 14 12 10 8 6 4 2 0 Sales H1 FY16 USA Aust Asia Latin America DWL Europe Sales H1 FY17 -2 5
Slide 6: EBITDA movement – H1 FY16 versus H1 FY17
EBITDA movement – H1 FY16 versus H1 FY17 3 2.5 2 1.5 1 0.5 0 EBITDA H1 FY16 Sales Margin Expenses Other Revenues FX EBITDA H1 FY17 6
Slide 7: H1 FY17 – Milestones achieved
H1 FY17 – Milestones achieved Full suite of new Grael (low Cost) products released, with shipments having commenced in Dec 2016 to US and other parts of the world. Curry 8 – the next generation of our world leading source localisation brain analysis software - released November 2016 (applicable
Slide 8: Revenue Composition at $16.2m for H1 FY17
Revenue Composition at $16.2m for H1 FY17 31 December 2016 By geographic region By product/market Supply Tech. Europe, Items, Service, 15% USA, Brain 10% 10% 29% Blood Flow, 15% Sleep, 35% Asia, Brain Aust, 41% Res, 15% Neuro, 20% 10% Software upgrades 5 to 10% of system sales Compumedics sells dire
Slide 9: Operating cash, Cash and Debt – trending positively
Operating cash, Cash and Debt – trending positively 6 5 4 3 AUD m 2 1 0 H1 FY12 H1 FY13 H1 FY14 H1 FY15 H1 FY16 H1 FY17 -1 Operating Cash Cash on hand Bank Debt 9
Slide 10: Core Business – Restored Net Cash Position
Core Business – Restored Net Cash Position $m FY12 FY13 FY14 FY15 FY16 H1 FY17 Cash 1.1 1.3 1.1 2.2 3.1 5.7 Trade receivables 8.7 8.1 8.6 9.8 11.9 10.9 Inventories 5.3 5.5 6.1 5.7 6.5 7.1 Prod. dev’t 4.0 3.5 2.9 2.7 2.4 2.4 Tax asset 0.0 0.0 0.0 0.0 0.5 0.5 PP&E 0.8 0.7 0.7 0.8 0.8 0.8 Other 0.0 0.0
Slide 11: Outlook
Outlook Profitability and operating cash remain positive, despite sales shortfall, validating changes made to product composition (new low cost Grael devices) and the selective outsourcing of production, along with other efficiency gains New leadership in place in US. US sales H1 FY2017 11% belo
Slide 12: Growth Platform – Core and Step-Out
Growth Platform – Core and Step-Out Sales – schematic only FY16F FY17F FY18F FY19F FY20F Core - Base Core - Sleep/Neuro - Mid Market Neuro - MEG Sleep - eHealth • Step-out - NEURO – BRAIN IMAGING – By signing the new MEG* Agreement with KRISS we can transition from a USD30k software sale to a USD4.0
Slide 13: Core Business – Premium Focus
Core Business – Premium Focus Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Research Global market – 250m 1,300m 20m 15m USD pa Compumedics market share 6% <1% 30% 35% (approximate) Aust – 1 Aust – 1 Aust – 1 Aust – 1 Compumedics USA – 2 USA – 3 USA –
Slide 14: Core Business – Adding Mid-Tier Range
Core Business – Adding Mid-Tier Range Average Product Used for Bought by selling price Hospitals, doctors Grael Sleep and neurology USD17,500 and service providers Hospitals, doctors Somte PSG Sleep USD10,000 and service providers Hospitals, doctors Siesta Sleep and neurology USD18,000 and service p
Slide 15: Next Generation Growth – Core and Step-out
Next Generation Growth – Core and Step-out Neuro Neuro Sleep Brain Blood Diagnostics – Diagnostics - Diagnostics Flow Diagnostics Clinic Imaging Cloud based sleep Leverage existing Long term epilepsy diagnostic platforms Leverage CURRY TCD technology and Next generation market penetration for both p
Slide 16: Core Business - Growth Drivers
Core Business - Growth Drivers Compumedics/NeuroScan LTEM innovative brain analysis software and high performance amplifiers are unrivalled world class technology We have >20,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumedics. Earnings initiativ
Slide 17: USA – CMP is number 3 Supplier
USA – CMP is number 3 Supplier USA Clinical Sales Force Expansion More sales representatives = more revenue for both sleep and neurology Past USD4.5m FY2016 to now USD6.4m FY2017 USD10.0m FY2018 USD15.0m 17
Slide 18: China - We are the number 1 Premier Supplier
China - We are the number 1 Premier Supplier Compumedics Clients in China Sleep Neuroscience Neuroscan 28 2 Xin Jiang 5 Helongjiang Inner Mongolia 2 Jilin Beijing 88 2 Liaoning Ningxia 23 Qinhuangdao China Sales (Orders taken) – USD’s QingHai 3 HeBei 10 3 Tianjin Dalian 2 3 16 12 Gansu 14 HeNan Welf
Slide 19: Step out 1 - Brain Imaging: Initial sale in FY17
Step out 1 - Brain Imaging: Initial sale in FY17 Opportunity Market & Competition Plan Outcome CMP’s CURRY brain The MEG market is currently H2 FY16 – sign LOI CMP plans to sell analysis software is already estimated at about 35 systems a with KRISS for license 1 MEG systems the gold standard for th
Slide 20: Step out – eHealth/cloud: Initial Nexus sales in US booked
Step out 2 – eHealth/cloud: Initial Nexus 360 sales in US booked eHealthMedics Operational systems have Compumedics are Key partners has already been developed for the cloud now approaching being locked in excess based capture, transfer a select group of pursued of $10m of and translation of medical
Slide 21: Directors & Executive Team Key Management
Directors & Executive Team Key Management David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 26yrs NED - Mr. Alan Anderson Mr. David Lawson Leading USA Attorney Chief Financial Officer CMP Tenure : 11 yrs & Company Secretary CMP Tenure 13 yrs Mr. Warwick Freeman Kerry Hubick, Ph.D. Mr. Chri
Slide 22: Investor Summary
Investor Summary Core business continues to grow with lower cost base and addition of mid-tier International sales force Compumedics remains expansion, neurology market committed to continuing to opportunity and earnings deliver superior returns to improvement initiatives to shareholders continue to
Slide 23: Disclaimer
Disclaimer This presentation has been prepared by Compumedics Ltd (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estim
Slide 24: compumedics.com.au
CG COMPUMEDICS Vs -—__/ ly compumedics.com.au